^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SAIL66

    i
    Other names: SAIL66, SAIL 66, SAIL-66
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CD3 agonist, CD137 agonist, CLDN6 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137. (PubMed, J Immunother Cancer)
    Our data demonstrate that SAIL66, designed to engage CLDN6, CD3, and CD137, has the potential to enhance antitumor activity and provide a potent therapeutic option for patients with ovarian and other solid tumors expressing CLDN6. Clinical trials are currently underway to evaluate the safety and efficacy of SAIL66.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CLDN6 (Claudin 6) • CD4 (CD4 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    CLDN6 expression • CLDN6 positive
    |
    SAIL66
    over1year
    A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=178, Recruiting, Chugai Pharmaceutical | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 positive
    |
    Actemra IV (tocilizumab) • SAIL66
    almost2years
    A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=178, Not yet recruiting, Chugai Pharmaceutical
    New P1 trial • Metastases
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 positive
    |
    Actemra IV (tocilizumab) • SAIL66